ACS Nano · 2021 · 56 citations · 48 references
PharmacyBioengineeringPharmaceutical BiotechnologyBiomaterialsDrug DeliveryPolymer ChemistryDiabetes ManagementDiabetes MellitusDrug Delivery EngineeringInsulin TherapyPolymeric Carrier SystemsPolymeric Drug Delivery SystemsBlood Glucose RegulationDrug Delivery PolymersGlucose-dependent Insulin SecretionGlucose-responsive MaterialsGlucose-responsive ReleaseGlucose-stimulated Insulin SecretionPolymers In Drug FormulationRelease Kinetics
Insulin therapy is the central component of treatment for type 1 and advanced type 2 diabetes; however, its narrow therapeutic window is associated with a risk of severe hypoglycemia. A glucose-responsive carrier that demonstrates consistent and slow basal insulin release under a normoglycemic condition and accelerated insulin release in response to hyperglycemia in real-time could offer effective blood glucose regulation with reduced risk of hypoglycemia. Here, we describe a poly(l-lysine)-derived biodegradable glucose-responsive cationic polymer for constructing polymer-insulin complexes for glucose-stimulated insulin delivery. The effects of the modification degree of arylboronic acid in the synthesized cationic polymer and polymer-to-insulin ratio on the glucose-dependent equilibrated free insulin level and the associated insulin release kinetics have been studied. In addition, the blood glucose regulation ability of these complexes and the associated glucose challenge-triggered insulin release are evaluated in type 1 diabetic mice.
48
Yasuo Ohkubo, Hideki Kishikawa, Eiichi Araki et al. · Diabetes Research and Clinical Practice · 1995 · 3.1K citations
Kazunori Kataoka, Hiroaki Miyazaki, Masayuki Bunya et al. · Journal of the American Chemical Society · 1998 · 583 citations